Urinary thymine dimers and 8-oxo-2'-deoxyguanosine in psoriasis.

Abstract

Psoralen in conjunction with UVA (PUVA) is perhaps the most effective treatment for psoriasis. It is, however, a risk factor for skin cancer in these patients and there is a need to develop non-invasive assays reflective of treatment-induced DNA damage. We report here the assessment of two important lesions, thymine dimer (T<>T) and 8-oxo-2'-deoxyguanosine (8-OHdG), in the urine of psoriasis patients. It was found that, once corrected for urine concentration, the psoriatic group had significantly higher (P<0. 0001) urinary levels of thymine dimers compared to the control group. No significant differences in urinary 8-OHdG levels were noted between the psoriatic, atopic dermatitis and control groups. Therefore biomonitoring of therapy from the very start with this simple and non-invasive assay could perhaps be an effective measure of the risk involved with the treatment allowing optimization for minimal-risk therapy.

• Authors: J Ahmad, M S Cooke, A Hussieni, M D Evans, K Patel, R M Burd, T O Bleiker, P E Hutchinson, J Lunec
• Journal: FEBS letters (FEBS Lett) Vol. 460 Issue 3 Pg. 549-53 (Nov 05 1999) ISSN: 0014-5793 [Print] England
• PMID: 10556533 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Pyrimidine Dimers
• Poly T
• 8-Hydroxy-2'-Deoxyguanosine
• Deoxyguanosine

Topics

• 8-Hydroxy-2'-Deoxyguanosine
• Adolescent
• Adult
• Aged
• Aged, 80 and over
• DNA Damage (genetics)
• Deoxyguanosine (analogs & derivatives, urine)
• Female
• Humans
• Male
• Middle Aged
• PUVA Therapy (adverse effects)
• Poly T (therapeutic use)
• Psoriasis (drug therapy, urine)
• Pyrimidine Dimers (urine)
• Risk Assessment